MX2009000285A - Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. - Google Patents

Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.

Info

Publication number
MX2009000285A
MX2009000285A MX2009000285A MX2009000285A MX2009000285A MX 2009000285 A MX2009000285 A MX 2009000285A MX 2009000285 A MX2009000285 A MX 2009000285A MX 2009000285 A MX2009000285 A MX 2009000285A MX 2009000285 A MX2009000285 A MX 2009000285A
Authority
MX
Mexico
Prior art keywords
activity
increase
compounds
substituted piperidines
methods
Prior art date
Application number
MX2009000285A
Other languages
English (en)
Inventor
Ronald J Doll
Matthew E Voss
Stephane L Bogen
Latha G Nair
Yaolin Wang
Rumin Zhang
Mark A Mccoy
Yao Ma
Brian R Lahue
Jr Gerald W Shipps
Yuan Tian
Zhuyan Guo
Weidong Pan
Elise M Siegel
Craig R Gibeau
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009000285A publication Critical patent/MX2009000285A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

En sus muchas modalidades, la presente invención describe nuevos compuestos como inhibidores de la proteína HDM2, métodos para preparar dichos compuestos, composiciones farmacéuticas que incluyen uno o varios de dichos compuestos, métodos de tratamiento, prevención e inhibición de una o varias enfermedades asociadas con la proteína HDM2 o P53 usando dichos compuestos o composiciones farmacéuticas.
MX2009000285A 2006-06-30 2007-06-27 Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. MX2009000285A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81775306P 2006-06-30 2006-06-30
PCT/US2007/014958 WO2008005268A1 (en) 2006-06-30 2007-06-27 Substituted piperidines that increase p53 activity and the uses thereof

Publications (1)

Publication Number Publication Date
MX2009000285A true MX2009000285A (es) 2009-06-08

Family

ID=38656615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000285A MX2009000285A (es) 2006-06-30 2007-06-27 Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.

Country Status (17)

Country Link
US (1) US7884107B2 (es)
EP (1) EP2035416A1 (es)
JP (1) JP2009542666A (es)
KR (1) KR20090042779A (es)
CN (1) CN101595107A (es)
AR (1) AR061726A1 (es)
AU (1) AU2007269836A1 (es)
BR (1) BRPI0713119A2 (es)
CA (1) CA2656398A1 (es)
CO (1) CO6150158A2 (es)
IL (1) IL196152A0 (es)
MX (1) MX2009000285A (es)
NO (1) NO20090469L (es)
PE (1) PE20081238A1 (es)
TW (1) TW200808781A (es)
WO (1) WO2008005268A1 (es)
ZA (1) ZA200900204B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157384A2 (en) 2007-06-15 2008-12-24 Microphage Incorporated Method of detection of microorganisms with enhanced bacteriophage amplification
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ATE485268T1 (de) * 2006-02-16 2010-11-15 Schering Corp Pyrrolidin-derivate als erk-hemmer
EP2037919A2 (en) * 2006-06-30 2009-03-25 Schering Corporation Method of using substituted piperidines that increase p53 activity
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
EP2224929B1 (en) 2007-12-17 2016-05-04 Janssen Pharmaceutica, N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
JP5276676B2 (ja) * 2008-02-21 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である化合物
MX2010010165A (es) 2008-03-17 2010-11-25 Scripps Research Inst Procedimientos quimicos y geneticos combinados para generacion de celulas madre pluripotentes inducidas.
AR073578A1 (es) * 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CA2734363C (en) 2008-09-18 2016-10-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
EP3312269A1 (en) 2008-12-17 2018-04-25 The Scripps Research Institute Generation and maintenance of stem cells
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
BR112012008849A2 (pt) * 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
CN105861446B (zh) 2009-10-16 2021-10-01 斯克里普斯研究所 多能细胞的诱导
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
EP2553086B1 (en) 2010-03-31 2017-04-19 The Scripps Research Institute Reprogramming cells
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
ES2670842T3 (es) 2010-06-15 2018-06-01 Cellular Dynamics International, Inc. Generación de células madre pluripotentes inducidas a partir de pequeños volúmenes de sangre periférica
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
BR112013014522A2 (pt) * 2010-12-16 2017-09-26 Roche Glycart Ag anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
KR102160721B1 (ko) 2010-12-22 2020-09-29 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
US9415103B2 (en) 2011-06-14 2016-08-16 Yeda Research And Development Co. Ltd. Combination therapy to prevent DCIS formation and progression to breast cancer
EP2732029B1 (en) 2011-07-11 2019-01-16 FUJIFILM Cellular Dynamics, Inc. Methods for cell reprogramming and genome engineering
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2771008A4 (en) 2011-10-28 2015-04-08 Merck Sharp & Dohme MACROCYCLES INCREASING P53 ACTIVITY AND USES THEREOF
EP2793890B1 (en) * 2011-12-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
WO2013123266A1 (en) * 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
CN102690826B (zh) * 2012-04-19 2014-03-05 山西医科大学 一种特异性降低人Aurora-A基因表达的shRNA及其应用
WO2014024993A1 (ja) * 2012-08-09 2014-02-13 国立大学法人京都大学 ピぺラジン誘導体およびその用途
US9603844B2 (en) * 2012-10-22 2017-03-28 Georgetown University Compositions and methods for treating mammary tumors
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
PT3013833T (pt) 2013-06-26 2019-03-20 Univ Do Porto Oxazoloisoindolinonas derivadas de triptofanol: ativadoras de molécula pequena da p53
US11268069B2 (en) 2014-03-04 2022-03-08 Fate Therapeutics, Inc. Reprogramming methods and cell culture platforms
US10576064B2 (en) 2014-07-03 2020-03-03 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN105597090B (zh) * 2014-11-14 2022-08-23 中国科学院上海营养与健康研究所 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
KR20170117450A (ko) 2015-02-18 2017-10-23 엔리벡스 테라퓨틱스 리미티드 암 치료를 위한 면역 요법 및 사이토카인 조절 요법의 조합
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
BR112017019738A2 (pt) 2015-03-20 2018-05-29 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
CA3000063A1 (en) 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
US11441126B2 (en) 2015-10-16 2022-09-13 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
CN108463548B (zh) 2015-10-30 2023-04-18 加利福尼亚大学董事会 由干细胞产生t细胞的方法及使用所述t细胞的免疫治疗方法
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
AU2017330620A1 (en) 2016-09-20 2019-03-28 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonists
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
AU2018248586A1 (en) 2017-04-05 2019-09-05 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
CN108864113B (zh) * 2018-08-03 2021-08-13 南方科技大学 一种mdm2-hdac双靶点抑制剂、药物组合物及其制备和用途
CN109293630A (zh) * 2018-11-15 2019-02-01 山东大学 含取代吡唑类化合物及其制备方法与应用
CN110643557B (zh) * 2019-04-23 2021-12-31 天津科技大学 一种基因工程菌的构建及其在高效催化5α-雄烯二酮生产中的应用
CN113633642A (zh) * 2021-08-26 2021-11-12 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) Abt-263在制备抑制角膜移植免疫排斥反应的药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09249566A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ピペリジン化合物含有ケモカイン受容体拮抗剤
WO1998016527A1 (en) * 1996-10-15 1998-04-23 Fujisawa Pharmaceutical Co., Ltd. Benzoxepine derivatives which promote release of growth hormone
JP2000514838A (ja) * 1997-05-14 2000-11-07 藤沢薬品工業株式会社 成長ホルモンの放出を促進するピペリジノ誘導体
EP0947494A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity
AU757217B2 (en) * 1998-05-11 2003-02-06 Helsinn Healthcare Sa Compounds with growth hormone releasing properties
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
AR035312A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Compuestos de acido hidroxamico que contienen alquinilo como inhibidores de metaloproteinasa de matriz/tace, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
RU2293735C2 (ru) * 2000-06-15 2007-02-20 Шеринг Корпорейшн Производные нор-секо химбацина, фармацевтическая композиция и способ ингибирования на их основе
US6403584B1 (en) 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
US20020099035A1 (en) * 2001-01-24 2002-07-25 Sandanayaka Vincent P. Method for preparing alpha-sulfonyl hydroxamic acid derivatives
AU2002366278B2 (en) 2001-12-18 2007-07-19 F. Hoffmann-La Roche Ag CIS-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
CN1182113C (zh) * 2002-07-19 2004-12-29 中国科学院上海有机化学研究所 2，5－cis－二取代的吡咯烷衍生物、合成方法及其用途
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7632920B2 (en) * 2003-04-10 2009-12-15 Schering Corporation Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
BRPI0511328A (pt) 2004-05-18 2007-12-04 Hoffmann La Roche cis-imidazolinas
US20070191604A1 (en) 2005-12-13 2007-08-16 Alan Cooper Novel compounds that are ERK inhibitors

Also Published As

Publication number Publication date
JP2009542666A (ja) 2009-12-03
TW200808781A (en) 2008-02-16
CO6150158A2 (es) 2010-04-20
BRPI0713119A2 (pt) 2012-04-17
IL196152A0 (en) 2009-09-22
KR20090042779A (ko) 2009-04-30
PE20081238A1 (es) 2008-09-04
ZA200900204B (en) 2010-01-27
EP2035416A1 (en) 2009-03-18
AU2007269836A1 (en) 2008-01-10
US20080004287A1 (en) 2008-01-03
WO2008005268A1 (en) 2008-01-10
CA2656398A1 (en) 2008-01-10
CN101595107A (zh) 2009-12-02
AR061726A1 (es) 2008-09-17
NO20090469L (no) 2009-03-27
US7884107B2 (en) 2011-02-08

Similar Documents

Publication Publication Date Title
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
PH12014500053A1 (en) Proteasome inhibitors
TW200714604A (en) Substituted heterocycles and the uses thereof
TW200801008A (en) Protein kinase inhibitors
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
TW200738659A (en) Novel compounds
EA200870019A1 (ru) Лактамовые соединения и способы их применения
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
MX2010014233A (es) Compuestos quimicos 251.
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
TW200734344A (en) Antibacterial agents